Biosimilars are biologic medicines that have been approved by Health Canada as highly similar to the original, already-approved brand version (or its reference product). This means there are no clinically meaningful differences between the biosimilar and the approved biologic product in terms of safety, purity and potency. Biosimilars offer an opportunity to provide a more affordable alternative to biologics and are used to treat serious diseases, such as certain kinds of cancer, autoimmune disorders and diabetes.
Mylan has one of the largest and most diverse portfolios of biosimilars and insulin analogs in the industry with 20 products on the market or in development and regulatory approvals for biosimilars in more than 65 countries.
Biosimilar medicines fill an urgent, unmet need for more alternatives to biologic therapies on the market. These important options aim to bring competition, increase access and provide savings for patients and the overall healthcare system.
Total Canadian spending on biologics continues to increase, accounting for $8.3 billion in 2018 up from %5.1 billion in 2013. In 2018, that $8.3 billion in spending represented only 1.1% of public and 2.4% of private claims. Of the top 10 most costly biologics in Canada, Mylan has 7 currently in development.
To learn more, visit Mylan’s Biosimilars Without Borders website.
To learn more about our product portfolio in the Canada, click here.